Label: DESLORATADINE- desloratadine tablet, orally disintegrating 

  • NDC Code(s): 55111-360-06, 55111-360-31, 55111-551-06, 55111-551-31
  • Packager: Dr. Reddy's Laboratories Limited
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated 10/13

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use desloratadine orally disintegrating tablets safely and effectively. See full prescribing information for desloratadine orally disintegrating tablets.  
    Desloratadine Orally Disintegrating Tablets for oral use  
    Initial U.S. Approval: 2001

    INDICATIONS AND USAGE

    Desloratadine orally disintegrating tablets are indicated for:

    • Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older. (1.1)
    • Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older. (1.2)

    DOSAGE AND ADMINISTRATION

    Dosage (by age):

    Adults and adolescents 12 years of age and over:

    • Desloratadine orally disintegrating tablets - one 5 mg tablet once daily or

    Children 6 to 11 years of age:

    • Desloratadine orally disintegrating tablets - one 2.5 mg tablet once daily (2)

    DOSAGE FORMS AND STRENGTHS

    • Desloratadine orally-disintegrating tablets - 5 mg (3)
    • Desloratadine orally-disintegrating tablets - 2.5 mg (3)

    CONTRAINDICATIONS

    • Hypersensitivity (4, 6.2)

    WARNINGS AND PRECAUTIONS

    • Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported. In such cases, stop desloratadine at once and consider alternative treatments. (5.1)

    ADVERSE REACTIONS

    • The most common adverse reactions (reported in ≥2% of adult and adolescent patients with allergic rhinitis and greater than placebo) were pharyngitis, dry mouth, myalgia, fatigue, somnolence, dysmenorrhea. (6.1)

    To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    USE IN SPECIFIC POPULATIONS

    • Renal impairment: dosage adjustment is recommended (2.5, 8.6, 12.3)

    • Hepatic impairment: dosage adjustment is recommended (2.5, 8.7, 12.3)

    See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

    Revised: 4/2011

    Close
  • FULL PRESCRIBING INFORMATION: CONTENTS*
  • 1 INDICATIONS AND USAGE

    1.1  Seasonal Allergic Rhinitis

    Desloratadine orally disintegrating tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older.

    1.2 Perennial Allergic Rhinitis

    Desloratadine orally disintegrating tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older.

    Close
  • 2 DOSAGE AND ADMINISTRATION

     Desloratadine orally disintegrating tablets may be taken without regard to meals. Place desloratadine orally disintegrating tablets on the tongue and allow to disintegrate before swallowing. Tablet disintegration occurs rapidly. Administer with or without water. Take tablet immediately after opening the blister.

    2.1 Adults and adolescents 12 years of age and over

    The recommended dose of desloratadine orally disintegrating tablets is one 5 mg tablet once daily.

    2.2 Children 6 to 11 years of age

    The recommended dose of desloratadine orally disintegrating tablet is one 2.5 mg tablet once daily.

    NOTE: Desloratadine orally disintegrating tablets are not recommended for use in pediatric patients under 6 years of age as desloratadine syrup is better suited for these patients.

    2.5 Adults with Hepatic or Renal Impairment

    In adult patients with liver or renal impairment, a starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [see Clinical Pharmacology (12.3)].

    Close
  • 3 DOSAGE FORMS AND STRENGTHS

    Desloratadine orally disintegrating tablets 2.5 mg are light red colored, speckled, round, flat, uncoated, beveled edged debossed with “R” on one side and “551” on the other side. 

    Desloratadine orally disintegrating tablets 5 mg are light red colored, speckled, round, flat, uncoated, beveled edged debossed with “RDY” on one side and “360” on the other side. 

    Close
  • 4 CONTRAINDICATIONS

    Desloratadine orally disintegrating tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)]

    Close
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions

    Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported after administration of desloratadine. If such a reaction occurs, therapy with desloratadine should be stopped and alternative treatment should be considered. [See Adverse Reactions (6.2)]

    Close
  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed in greater detail in other sections of the label:

    • Hypersensitivity reactions [See Warnings and Precautions (5.1).]

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. 

    Adults and Adolescents

    Allergic Rhinitis: In multiple-dose placebo-controlled trials, 2,834 patients ages 12 years or older received desloratadine tablets at doses of 2.5 mg to 20 mg daily, of whom 1,655 patients received the recommended daily dose of 5 mg. In patients receiving 5 mg daily, the rate of adverse events was similar between desloratadine and placebo-treated patients. The percent of patients who withdrew prematurely due to adverse events was 2.4% in the desloratadine group and 2.6% in the placebo group. There were no serious adverse events in these trials in patients receiving desloratadine. All adverse events that were reported by greater than or equal to 2% of patients who received the recommended daily dose of desloratadine tablets (5 mg once daily), and that were more common with desloratadine tablets than placebo, are listed in Table 1.

    Table 1

    Incidence of Adverse Events Reported by ≥2% of Adult and Adolescent Allergic Rhinitis Patients Receiving Desloratadine Tablets

    Adverse Event DesloratadineTablets 5 mg
    (n=1,655)
    Placebo 
    (n=1,652)
    Infections and Infestations
       Pharyngitis 4.1% 2.0%
    Nervous System Disorders
       Somnolence 2.1% 1.8%
    Gastrointestinal Disorders
       Dry Mouth 3.0% 1.9%
    Musculoskeletal and Connective Tissue Disorders
       Myalgia 2.1% 1.8%
    Reproductive System and Breast Disorders
       Dysmenorrhea 2.1% 1.6%
    General Disorders and Administration Site Conditions
       Fatigue 2.1% 1.2%

    The frequency and magnitude of laboratory and electrocardiographic abnormalities were similar in desloratadine and placebo-treated patients.

    There were no differences in adverse events for subgrous of patients as defined by gender, age, or race.

    Pediatrics

    Two hundred and forty-six pediatric subjects 6 months to 11 years of age received desloratadine for 15 days in three placebo-controlled clinical trials. Pediatric subjects aged 6 to 11 years received 2.5 mg once a day, subjects aged 1 to 5 years received 1.25 mg once a day, and subjects 6 to 11 months of age received 1 mg once a day. 

    In subjects 6 to 11 years of age, no individual adverse event was reported by 2 percent or more of the subjects.  

    In subjects 2 to 5 years of age, adverse events reported for desloratadine and placebo in at least 2 percent of subjects receiving desloratadine and at a frequency greater than placebo were fever (5.5%, 5.4%), urinary tract infection (3.6%, 0%) and varicella (3.6%, 0%). 

    In subjects 12 months to 23 months of age, adverse events reported for the desloratadine product and placebo in at least 2 percent of subjects receiving desloratadine and at a frequency greater than placebo were fever (16.9%, 12.9%), diarrhea (15.4%, 11.3%), upper respiratory tract infections (10.8%, 9.7%), coughing (10.8%, 6.5%), appetite increased (3.1%, 1.6%), emotional lability (3.1%, 0%), epistaxis (3.1%, 0%), parasitic infection (3.1%, 0%), pharyngitis (3.1%, 0%), rash maculopapular (3.1%, 0%). 

    In subjects 6 months to 11 months of age, adverse events reported for desloratadine and placebo in at least 2 percent of subjects receiving desloratadine and at a frequency greater than placebo were upper respiratory tract infections (21.2%, 12.9%), diarrhea (19.7%, 8.1%), fever (12.1%, 1.6%), irritability (12.1%, 11.3%), coughing (10.6%, 9.7%), somnolence (9.1%, 8.1%), bronchitis (6.1%, 0%), otitis media (6.1%, 1.6%), vomiting (6.1%, 3.2%), anorexia (4.5%, 1.6%), pharyngitis (4.5%, 1.6%), insomnia (4.5%, 0%), rhinorrhea (4.5%, 3.2%), erythema (3%, 1.6%), and nausea (3%, 0%). 

    There were no clinically meaningful changes in any electrocardiographic parameter, including the QTc interval. Only one of the 246 pediatric subjects receiving desloratadine in the clinical trials discontinued treatment because of an adverse event.

    6.2 Post-Marketing Experience

    Because adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following spontaneous adverse events have been reported during the marketing of desloratadine: tachycardia, palpitations, rare cases of hypersensitivity reactions (such as rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis), psychomotor hyperactivity, seizures, and elevated liver enzymes including bilirubin, and very rarely, hepatitis.

    Close
  • 7 DRUG INTERACTIONS

    7.1 Inhibitors of Cytochrome P450 3A4

    In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxy desloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]

    7.2 Fluoxetine

    In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]

    7.3 Cimetidine

    In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine   H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]

    Close
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, desloratadine should be used during pregnancy only if clearly needed.

    Desloratadine was not teratogenic in rats or rabbits at approximately 210 and 230 times, respectively, the area under the concentration-time curve (AUC) in humans at the recommended daily oral dose. An increase in pre-implantation loss and a decreased number of implantations and fetuses were noted, however, in a separate study in female rats at approximately 120 times the AUC in humans at the recommended daily oral dose. Reduced body weight and slow righting reflex were reported in pups at approximately 50 times or greater than the AUC in humans at the recommended daily oral dose. Desloratadine had no effect on pup development at approximately 7 times the AUC in humans at the recommended daily oral dose. The AUCs in comparison referred to the desloratadine exposure in rabbits and the sum of desloratadine and its metabolites exposures in rats, respectively. [See Nonclinical Toxicology (13.2).

    8.3 Nursing Mothers

    Desloratadine passes into breast milk; therefore, a decision should be made whether to discontinue nursing or to discontinue desloratadine, taking into account the benefit of the drug to the nursing mother and the possible risk to the child.

    8.4 Pediatric Use

    The desloratadine orally disintegrating 2.5 mg tablet has not been evaluated in pediatric patients. Bioequivalence of the desloratadine orally disintegrating tablet and the previously marketed orally disintegrating tablet was established in adults. In conjunction with the dose finding studies in pediatrics described, the pharmacokinetic data for desloratadine orally disintegrating tablet supports the use of the 2.5 mg dose strength in pediatric patients 6 to 11 years of age.

    8.5 Geriatric Use

    Clinical studies of desloratadine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identifiied differences between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [See Clinical Pharmacology (12.3)]

    8.6 Renal Impairment

    Dosage adjustment for patients with renal impairment is recommended [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].

    8.7 Hepatic Impairment

    Dosage adjustment for patients with hepatic impairment is recommended [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]

    Close
  • 9 DRUG ABUSE AND DEPENDENCE

    There is no information to indicate that abuse or dependency occurs with desloratadine tablets.

    Close
  • 10 OVERDOSAGE

    In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Desloratadine and 3-hydroxydesloratadine are not eliminated by hemodialysis.

    Information regarding acute overdosage is limited to experience from post-marketing adverse event reports and from clinical trials conducted during the development of the desloratadine product. In a dose-ranging trial, at doses of 10 mg and 20 mg/day somnolence was reported.

    In another study, no clinically relevant adverse events were reported in normal male and female volunteers who were given single daily doses of desloratadine 45 mg for 10 days [See Clinical Pharmacology (12.2)].

    Lethality occurred in rats at oral doses of 250 mg/kg or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUC in humans at the recommended daily oral dose). The oral median lethal dose in mice was 353 mg/kg (estimated desloratadine exposures were approximately 290 times the human daily oral dose on a mg/m2 basis). No deaths occurred at oral doses up to 250 mg/kg in monkeys (estimated desloratadine exposures were approximately 810 times the human daily oral dose on a mg/m2 basis).

    Close
  • 11 DESCRIPTION

    The desloratadine orally disintegrating tablets light red colored, speckled, round, flat, uncoated, beveled edged debossed with “R” on one side and “551” on the other side for the 2.5 mg tablets and a “light red colored, speckled, round, flat, uncoated, beveled edged debossed with “RDY” on one side and “360” on the other side  for the 5 mg tablets. Each orally disintegrating tablet contains either 5 mg or 2.5 mg of desloratadine. It also contains the following inactive ingredients: anhydrous citric acid, aspartame, colloidal silicon dioxide, crospovidone, ferric oxide, mannitol, lactose anhydrous, microcrystalline cellulose, polacrilex resin, sodium stearyl fumarate, talc, tutti frutti flavor. 

    Desloratadine is a white to light pink colored powder that is soluble in dichloromethane. It has an molecular formula: C19H19ClN2 and a molecular weight of 310.8. The chemical name is 8-chloro-6,11-dihydro-11-(4-piperdinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine and has the following structure:

    structure

    Close
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H1-receptor. Desloratadine inhibited histamine release from human mast cells in vitro. Results of a radiolabeled tissue distribution study in rats and a radioligand H1-receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this finding is unknown.

    12.2 Pharmacodynamics

    Wheal and Flare: Human histamine skin wheal studies following single and repeated 5 mg doses of desloratadine have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal tachyphylaxis within the desloratadine 5 mg group over the 28-day treatment period. The clinical relevance of histamine wheal skin testing is unknown.

    Effects on QTc: Single daily doses of 45 mg were given to normal male and female volunteers for 10 days. All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In desloratadine-treated subjects, there was an increase in mean heart rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate (QTc) by both the Bazett and Fridericia methods. Using the QTc (Bazett) there was a mean increase of 8.1 msec in desloratadine-treated subjects relative to placebo. Using QTc (Fridericia) there was a mean increase of 0.4 msec in desloratadine-treated subjects relative to placebo. No clinically relevant adverse events were reported.

    12.3 Pharmacokinetics

    Absorption

    The pharmacokinetic profile of desloratadine orally disintegrating tablets was evaluated in a three way crossover study in 24 adult volunteers. A single desloratadine orally disintegrating tablets containing 5 mg of desloratadine was bioequivalent to a single 5 mg desloratadine orally disintegrating tablets (original formulation) for both desloratadine and 3-hydroxydesloratadine. Food and water had no effect on the bioavailability (AUC and Cmax) of desloratadine orally disintegrating tablets.

    Distribution

    Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89% bound to plasma proteins, respectively. Protein binding of desloratadine and 3-hydroxydesloratadine was unaltered in subjects with impaired renal function.

    Metabolism

    Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. The enzyme(s) responsible for the formation of 3-hydroxydesloratadine have not been identified. Data from clinical trials indicate that a subset of the general population has a decreased ability to form 3-hydroxydesloratadine, and are poor metabolizers of desloratadine. In pharmacokinetic studies (n=3,748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours). These pharmacokinetic studies included subjects between the ages of 2 and 70 years, including 977 subjects aged 2 to 5 years, 1,575 subjects aged 6 to 11 years, and 1196 subjects aged 12 to 70 years. There was no difference in the prevalence of poor metabolizers across age groups. The frequency of poor metabolizers was higher in Blacks (17%, n=988) as compared to Caucasians (2%, n=1,462) and Hispanics (2%, n=1,063). The median exposure (AUC) to desloratadine in the poor metabolizers was approximately 6-fold greater than in the subjects who are not poor metabolizers. Subjects who are poor metabolizers of desloratadine cannot be prospectively identified and will be exposed to higher levels of desloratadine following dosing with the recommended dose of desloratadine. In multidose clinical safety studies, where metabolizer status was identified, a total of 94 poor metabolizers and 123 normal metabolizers were enrolled and treated with desloratadine oral solution for 15 to 35 days. In these studies, no overall differences in safety were observed between poor metabolizers and normal metabolizers. Although not seen in these studies, an increased risk of exposure-related adverse events in patients who are poor metabolizers cannot be ruled out.

    Elimination

    The mean plasma elimination half-life of desloratadine was approximately 27 hours. Cmax andAUC values increased in a dose proportional manner following single oral doses between 5 and 20 mg. The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency. A human mass balance study documented a recovery of approximately 87% of the 14C-desloratadine dose, which was equally distributed in urine and feces as metabolic products. Analysis of plasma 3-hydroxydesloratadine showed similar Tmax and half-life values compared to desloratadine.

    Special Populations

    Geriatric Subjects: In older subjects (³65 years old; n=17) following multiple-dose administration of desloratadine tablets, the mean Cmax and AUC values for desloratadine were 20% greater than in younger subjects (<65 years old). The oral total body clearance (CL/F) when normalized for body weight was similar between the two age groups. The mean plasma elimination half-life of desloratadine was 33.7 hr in subjects ³65 years old. The pharmacokinetics for 3-hydroxydesloratadine appeared unchanged in older versus younger subjects. These age-related differences are unlikely to be clinically relevant and no dosage adjustment is recommended in elderly subjects.

    Pediatric Subjects: In subjects 6 to 11 years old, a single dose of 5 mL of desloratadine oral solution containing 2.5 mg of desloratadine, resulted in desloratadine plasma concentrations similar to those achieved in adults administered a single 5 mg desloratadine tablet. In subjects 2 to 5 years old, a single dose of 2.5 mL of desloratadine Oral Solution containing 1.25 mg of desloratadine, resulted in desloratadine plasma concentrations similar to those achieved in adults administered a single 5 mg desloratadine tablet. However, the Cmax and AUC of the metabolite (3-hydroxydesloratadine) were 1.27 and 1.61 times higher for the 5 mg dose of Oral Solution administered in adults compared to the Cmax and AUC obtained in children 2 to 11 years of age receiving 1.25 to 2.5 mg of desloratadine oral solution. 

    A single dose of either 2.5 mL or 1.25 mL of desloratadine oral solution containing 1.25 mg or 0.625 mg, respectively, of desloratadine was administered to subjects 6 to 11 months of age and 12 to 23 months of age. The results of a population pharmacokinetic analysis indicated that a dose of 1 mg for subjects aged 6 to 11 months and 1.25 mg for subjects 12 to 23 months of age is required to obtain desloratadine plasma concentrations similar to those achieved in adults administered a single 5 mg dose of desloratadine oral solution. 

    The desloratadine orally disintegrating tablet 2.5 mg tablet has not been evaluated in pediatric patients. Bioequivalence of the desloratadine orally disintegrating tablet and the original desloratadine orally disintegrating tablet was established in adults. In conjunction with the dose-finding studies in pediatrics described, the pharmacokinetic data for desloratadine orally disintegrating tablets supports the use of the 2.5 mg dose strength in pediatric patients 6 to 11 years of age. 

    Renally Impaired: Desloratadine pharmacokinetics following a single dose of 7.5 mg were characterized in patients with mild (n=7; creatinine clearance 51 to 69 mL/min/1.73 m2), moderate (n=6; creatinine clearance 34 to 43 mL/min/1.73 m2), and severe (n=6; creatinine clearance 5 to 29 mL/min/1.73 m2) renal impairment or hemodialysis dependent (n=6) patients. In patients with mild and moderate renal impairment, median Cmax and AUC values increased by approximately 1.2- and 1.9-fold, respectively, relative to subjects with normal renal function. In patients with severe renal impairment or who were hemodialysis dependent, Cmax and AUC values increased by approximately 1.7- and 2.5-fold, respectively. Minimal changes in 3-hydroxydesloratadine concentrations were observed. Desloratadine and 3-hydroxydesloratadine were poorly removed by hemodialysis. Plasma protein binding of desloratadine and 3-hydroxydesloratadine was unaltered by renal impairment. Dosage adjustment for patients with renal impairment is recommended [see Dosage and Administration (2.5)].

    Hepatically Impaired: Desloratadine pharmacokinetics were characterized following a single oral dose in patients with mild (n=4), moderate (n=4), and severe (n=4) hepatic impairment as defined by the Child-Pugh classification of hepatic function and 8 subjects with normal hepatic function. Patients with hepatic impairment, regardless of severity, had approximately a 2.4-fold increase in AUC as compared with normal subjects. The apparent oral clearance of desloratadine in patients with mild, moderate, and severe hepatic impairment was 37%, 36%, and 28% of that in normal subjects, respectively. An increase in the mean elimination half-life of desloratadine in patients with hepatic impairment was observed. For 3-hydroxydesloratadine, the mean Cmax and AUC values for patients with hepatic impairment were not statistically significantly different from subjects with normal hepatic function. Dosage adjustment for patients with hepatic impairment is recommended [see Dosage and Administration (2.5)].

    Gender: Female subjects treated for 14 days with desloratadine tablets had 10% and 3% higher desloratadine Cmax and AUC values, respectively, compared with male subjects. The 3-hydroxydesloratadine Cmax and AUC values were also increased by 45% and 48%, respectively, in females compared with males. However, these apparent differences are not likely to be clinically relevant and therefore no dosage adjustment is recommended.

    Race: Following 14 days of treatment with desloratadine tablets, the Cmax and AUC values for desloratadine were 18% and 32% higher, respectively, in Blacks compared with Caucasians. For 3-hydroxydesloratadine there was a corresponding 10% reduction in Cmax and AUC values in Blacks compared to Caucasians. These differences are not likely to be clinically relevant and therefore no dose adjustment is recommended.

    Drug Interactions: In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) and female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days. In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady-state conditions to normal healthy male and female volunteers. Although increased plasma concentrations (Cmax and AUC0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed (see Table 2), there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.

    Table 2

    Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers

    Desloratadine 3-Hydroxydesloratadine
    Cmax AUC
    0-24hrs
    Cmax AUC
    0-24hrs
    Erythromycin
    (500 mg Q8h)
    + 24% + 14% + 43% + 40%
    Ketoconazole
    (200 mg Q12h)
    + 45% + 39% + 43% + 72%
    Azithromycin (500 mg day
    1,250 mg QD x 4 days)
    + 15% + 5% + 15% + 4%
    Fluoxetine
    (200 mg QD)
    + 15% + 0% + 17% + 13%
    Cimetidine
    (600 mg Q12h)
    + 12% + 19% - 11% - 3%
    Close
  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

    Carcinogenicity Studies:

    The carcinogenic potentialof desloratadine was assessed using a loratadine study in rats and a desloratadine study in mice. In a 2-year study in rats, loratadine was administered in the diet at doses up to 25 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 30 times the AUC in humans at the recommended daily oral dose). A significantly higher incidence of hepatocellular tumors (combined adenomas and carcinomas) was observed in males given 10 mg/kg/day of loratadine and in males and females given 25 mg/kg/day of loratadine. The estimated desloratadine and desloratadine metabolite exposures in rats given 10 mg/kg of loratadine were approximately 7 times the AUC in humans at the recommended daily oral dose. The clinical significance of these findings during long-term use of desloratadine is not known.

    In a 2 year dietary study in mice, males and females given up to 16 mg/kg/day and 32 mg/kg/day desloratadine, respectively, did not show significant increases in the incidence of any tumors. The estimated desloratadine and desloratadine metabolite exposures in mice at these doses were 12 and 27 times, respectively, the AUC in humans at the recommended daily oral dose.

    Genotoxicity Studies:

    In genotoxicity studies with desloratadine, there was no evidence of genotoxic potential in a reverse mutation assay (Salmonella/E. coli mammalian microsome bacterial mutagenicity assay) or in 2 assays for chromosomal aberrations (human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow micronucleus assay).

    Impairment of Fertility:

    There was no effect on female fertility in rats at desloratadine doses up to 24 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 130 times the AUC in humans at the recommended daily oral dose). A male specific decrease in fertility, demonstrated by reduced female conception rates, decreased sperm numbers and motility, and histopathologic testicular changes, occurred at an oral desloratadine dose of 12 mg/kg in rats (estimated desloratadine and desloratadine metabolite exposures were approximately 45 times the AUC in humans at the recommended daily oral dose). Desloratadine had no effect on fertility in rats at an oral dose of 3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 8 times the AUC in humans at the recommended daily oral dose).

    13.2 Animal Pharmacology and/or Toxicology

    Reproductive Toxicology Studies:

    Desloratadine was not teratogenic in rats at doses up to 48 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 210 times the AUC in humans at the recommended daily oral dose) or in rabbits at doses up to 60 mg/kg/day (estimated desloratadine exposures were approximately 230 times the AUC in humans at the recommended daily oral dose). In a separate study, an increase in pre-implantation loss and a decreased number of implantations and fetuses were noted in female rats at 24 mg/kg (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUC in humans at the recommended daily oral dose). Reduced body weight and slow righting reflex were reported in pups at doses of 9 mg/kg/day or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 50 times or greater than the AUC in humans at the recommended daily oral dose). Desloratadine had no effect on pup development at an oral dose of 3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 7 times the AUC in humans at the recommended daily oral dose).

    Close
  • 14 CLINICAL STUDIES

    14.1 Seasonal Allergic Rhinitis

    The clinical efficacy and safety of desloratadine tablets were evaluated in over 2,300 patients 12 to 75 years of age with seasonal allergic rhinitis. A total of 1,838 patients received 2.5 to 20 mg/day of desloratadine in 4 double-blind, randomized, placebo-controlled clinical trials of 2 to 4 weeks’ duration conducted in the United States. The results of these studies demonstrated the efficacy and safety of desloratadine 5 mg in the treatment of adult and adolescent patients with seasonal allergic rhinitis. In a dose-ranging trial, desloratadine 2.5 to 20 mg/day was studied. Doses of 5, 7.5, 10, and 20 mg/day were superior to placebo; and no additional benefit was seen at doses above 5.0 mg. In the same study, an increase in the incidence of somnolence was observed at doses of 10 mg/day and 20 mg/day (5.2% and 7.6%, respectively), compared to placebo (2.3%).

    In two 4 week studies of 924 patients (aged 15 to 75 years) with seasonal allergic rhinitis and concomitant asthma, desloratadine tablets 5 mg once daily improved rhinitis symptoms, with no decrease in pulmonary function. This supports the safety of administering desloratadine tablets to adult patients with seasonal allergic rhinitis with mild to moderate asthma.

    Desloratadine tablets 5 mg once daily significantly reduced the Total Symptom Score (the sum of individual scores of nasal and non-nasal symptoms) in patients with seasonal allergic rhinitis. See Table 3.

    Table 3

    TOTAL SYMPTOM SCORE (TSS)

    Changes in a 2 Week Clinical Trial in Patients with Seasonal Allergic Rhinitis

    Treatment Group
    (n)
    Mean Baseline*
    (SEM)
    Change from Baseline**
    (SEM)
    Placebo Comparison
    (P-value)
    Desloratadine
    5.0 mg (171)
    14.2 (0.3) -4.3 (0.3) P<0.01
    Placebo (173) 13.7 (0.3) -2.5 (0.3)  
    *At baseline, a total nasal symptom score (sum of 4 individual symptoms) of at least 6 and a total non-nasal symptom score (sum of 4 individual symptoms) of at least 5 (each symptom scored 0 to 3 where 0=no symptom and 3=severe symptoms) was required for trial eligibility. TSS ranges from 0=no symptoms to 24=maximal symptoms.
    **Mean reduction in TSS averaged over the 2-week treatment period.
    SEM=Standard Error of the Mean

    There were no significant differences in the effectiveness of desloratadine tablets 5 mg across subgroups of patients defined by gender, age, or race.

    14.2 Perennial Allergic Rhinitis

    The clinical efficacy and safety of desloratadine tablets 5 mg were evaluated in over 1,300 patients 12 to 80 years of age with perennial allergic rhinitis. A total of 685 patients received 5 mg/day of desloratadine in two double-blind, randomized, placebo-controlled clinical trials of 4 weeks’ duration conducted in the United States and internationally. In one of these studies desloratadine tablets 5 mg once daily was shown to significantly reduce the Total Symptom Score in patients with perennial allergic rhinitis (Table 4).

    Table 4

    TOTAL SYMPTOM SCORE (TSS)

    Changes in a 4 Week Clinical Trial in Patients with Perennial Allergic Rhinitis

    Treatment Group
    (n)
    Mean Baseline*(SEM) Change fromBaseline**(SEM) Placebo Comparison
    (P-value)
    Desloratadine
    5.0 mg (337)
    12.37 (0.18) -4.06 (0.21) P=0.01
    Placebo (337) 12.30 (0.18) -3.27 (0.21)  
    *At baseline, average of total symptom score (sum of 5 individual nasal symptoms and 3 non-nasal symptoms, each symptom scored 0 to 3 where 0=no symptom and 3=severe symptoms) of at least 10 was required for trial eligibility. TSS ranges from 0=no symptoms to 24=maximal symptoms.
    **Mean reduction in TSS averaged over the 4-week treatment period.
    SEM=Standard Error of the Mean

    Close
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Desloratadine Orally Disintegrating Tablets 2.5 mg: Desloratadine tablets 2.5 mg are light red colored, speckled, round, flat, uncoated, beveled edged debossed with “R” on one side and “551” on the other side and are supplied in carton of 5 packs containing 6 tablets each.

    Carton of 5 packs (NDC 55111-551-31), each pack containing 6 tablets (55111-551-06)

    Desloratadine Orally Disintegrating Tablets 5 mg: Desloratadine tablets 5 mg are light red colored, speckled, round, flat, uncoated, beveled edged debossed with “RDY” on one side and “360” on the other side and are supplied in carton of 5 packs containing 6 tablets each.

    Carton of 5 packs (NDC 55111-360-31), each pack containing 6 tablets (55111-360-06)

    Storage:

    Store orally disintegrating tablets at 20°-25°C (68°-77°F) excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].

    Close
  • 17 PATIENT COUNSELING INFORMATION

    [See FDA-Approved Patient Labeling]

    17.1 Information for Patients

    • Patients should be instructed to use desloratadine as directed.
    • As there are no food effects on bioavailability, patients can be instructed that desloratadine orally disintegrating tablets, may be taken without regard to meals.
    • Patients should be advised not to increase the dose or dosing frequency as studies have not demonstrated increased effectiveness at higher doses and somnolence may occur.
    • Phenylketonurics: Desloratadine orally disintegrating tablets contain phenylalanine 10.10 mg per 5 mg or 5 mg per 2.5 mg desloratadine orally disintegrating tablets.

    Close
  • PATIENT PACKAGE INSERT

    PATIENT INFORMATION 

    Desloratadine Orally Disintegrating Tablets

    Read the Patient Information that comes with desloratadine before you start taking it and each time you get a refill. There may be new information. This leaflet is a summary of the information for patients. Your doctor or pharmacist can give you additional information. This leaflet does not take the place of talking to your doctor about your medical condition or treatment.

    What is desloratadine?

    Desloratadine is a prescription medicine that contains the medicine desloratadine (an antihistamine).

    Desloratadine is used to help control the symptoms of:

    • seasonal allergic rhinitis (sneezing, stuffy nose, runny nose and itching of the nose) in people 2 years of age and older.
    • perennial allergic rhinitis (sneezing, stuffy nose, runny nose and itching of the nose) in people 6 months of age and older.

    Desloratadine is not for children younger than 6 months of age.  

    Who should not take desloratadineorally disintegrating tablets?

    Do not take desloratadine if you:

    • are allergic to desloratadine or any of the ingredients in desloratadine orally disintegrating tablets. See the end of this leaflet for a complete list of ingredients.
    • are allergic to loratadine (Alavert, Claritin).

    Talk to your doctor before taking this medicine if you have any questions about whether or not to take this medicine.

    What should I tell my doctor before taking desloratadineorally disintegrating tablets?

    Before you take desloratadine, tell your doctor if you:

    • have liver or kidney problems.
    • have any other medical conditions.
    • are pregnant or plan to become pregnant. It is not known if desloratadine will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.
    • are breast-feeding or plan to breast-feed. Desloratadine can pass into your breast milk. Talk to your doctor about the best way to feed your baby if you take desloratadine.

    Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Desloratadine may affect the way other medicines work, and other medicines may affect how desloratadine works. Especially tell your doctor if you take:

    • ketoconazole (Nizoral)
    • erythromycin (Ery-tab, Eryc, PCE)
    • azithromycin (Zithromax, Zmax)
    • antihistaminesfluoxetine (Prozac)
    • cimetidine (Tagamet)

    Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.

    How should I take desloratadineorally disintegrating tablets?

    • Take desloratadine exactly as your doctor tells you to take it.
    • Do not change your dose of desloratadine or take more often than prescribed. 
      • Place desloratadine orally disintegrating tablets on your tongue and allow it to dissolve before swallowing. Desloratadine orally disintegrating tablets can be taken with or without water. Take your desloratadine orally disintegrating tablets right away after opening the blister. 
    • If you take too much desloratadine, call your doctor or get medical attention right away.


      What are the possible side effects of desloratadine orally disintegrating tablets?

    Desloratadine may cause serious side effects, including:

    • Allergic reactions. Stop taking desloratadine and call your doctor right away or get emergency help if you have any of these symptoms:
      • rash
      • itching
      • hives
      • swelling of your lips, tongue, face, and throat
      • shortness of breath or trouble breathing 

    The most common side effects of desloratadine in adults and children 12 years of age and older with allergic rhinitis include:

    • sore throatd
    • dry mouth
    • muscle pain
    • tiredness
    • sleepiness
    • menstrual pain

    Increased sleepiness or tiredness can happen if you take more desloratadine than your doctor prescribed to you.

    Tell your doctor if you have any side effect that bothers you or that does not go away.

    These are not all of the possible side effects of desloratadine. For more information, ask your doctor or pharmacist.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    How should I store desloratadine orally disintegrating tablets?

    Store oraly disintegrating tablets at 20°-25°C (68°-77°F) excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].

    Keep desloratadine orally disintegrating tablets, and all medicines out of the reach of children.

    General information about desloratadine

    Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use desloratadine for a condition for which it was not prescribed. Do not give desloratadine to other people, even if they have the same condition you have. It may harm them. 

    This Patient Information leaflet summarizes the most important information about desloratadine. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about desloratadine that is written for health professionals. 

    What are the ingredients in desloratadine orally disintegrating tablets?

    Active ingredient: desloratadine

    Patients with Phenylketonuria: Desloratadine orally disintegrating tablets 5 mg contain 10.10 mg phenylalanine, and desloratadine orally disintegrating tablets 2.5 mg contain 5 mg phenylalanine.

    Inactive ingredients in desloratadine tablets: anhydrous citric acid, aspartame, colloidal silicon dioxide, crospovidone, ferric oxide, mannitol, lactose anhydrous, microcrystalline cellulose, polacrilex resin, sodium stearyl fumarate, talc, tutti frutti flavor. 

    To reorder additional Patient Information Sheets, contact Dr. Reddy’s Customer Service at 1-866-733-3952.

    Close
  • SPL UNCLASSIFIED SECTION

    Rx Only

    Manufactured by:

    Dr. Reddy's Laboratories Limited

    Bachupally - 500 090 INDIA

    Revised: 1013

    Close
  • Package Label. Principal Display Panel

    Desloratadine Orally Disintegrating Tablets, 2.5 mg - Blister Carton Label

    carton1

    Close
  • PRINCIPAL DISPLAY PANEL

    Desloratadine Orally Disintegrating Tablets, 5 mg - Blister Carton Label

    carton2

    Close
  • INGREDIENTS AND APPEARANCE
    DESLORATADINE 
    desloratadine tablet, orally disintegrating
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:55111-551
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Desloratadine (Desloratadine) Desloratadine 2.5 mg
    Inactive Ingredients
    Ingredient Name Strength
    SILICON DIOXIDE  
    anhydrous citric acid  
    ASPARTAME  
    crospovidone  
    FERRIC OXIDE RED  
    MANNITOL  
    ANHYDROUS LACTOSE  
    CELLULOSE, MICROCRYSTALLINE  
    POLACRILIN  
    sodium stearyl fumarate  
    TALC  
    Product Characteristics
    Color RED Score no score
    Shape ROUND Size 7mm
    Flavor TUTTI FRUTTI Imprint Code R;551
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55111-551-31 5 in 1 CARTON
    1 6 in 1 BLISTER PACK
    2 NDC:55111-551-06 6 in 1 BLISTER PACK
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA078367 01/11/2013
    DESLORATADINE 
    desloratadine tablet, orally disintegrating
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:55111-360
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Desloratadine (Desloratadine) Desloratadine 5 mg
    Inactive Ingredients
    Ingredient Name Strength
    SILICON DIOXIDE  
    anhydrous citric acid  
    ASPARTAME  
    crospovidone  
    FERRIC OXIDE RED  
    MANNITOL  
    ANHYDROUS LACTOSE  
    CELLULOSE, MICROCRYSTALLINE  
    POLACRILIN  
    sodium stearyl fumarate  
    TALC  
    Product Characteristics
    Color RED Score no score
    Shape ROUND Size 9mm
    Flavor TUTTI FRUTTI Imprint Code RDY;360
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55111-360-31 5 in 1 CARTON
    1 6 in 1 BLISTER PACK
    2 NDC:55111-360-06 6 in 1 BLISTER PACK
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA078367 01/11/2013
    Labeler - Dr. Reddy's Laboratories Limited (650562841)
    Establishment
    Name Address ID/FEI Business Operations
    Dr. Reddy's Laboratories Limited - FTO 3 918608162 analysis(55111-551, 55111-360), manufacture(55111-551, 55111-360)
    Close